In the coming days the Precision Nanomedicine journal will see the light, in its online version that is already being finalised. Dr. Simón Schwartz Jr, director of CIBBIM-Nanomedicine, is one of only two Spanish researchers who are part of the...
Read moreThe team of Dr. Simó Schwartz Jr gets a polymeric nanomedicine which facilitates concurrent therapies of pharmacological and gene silencing
One of the main problems that nanomedicine must face is the improvement of drugs transport and release systems to the correct place of action. And in particular, to take nucleic acids to the right target cells. The team led by Dr. Simó Schwartz...
Read moreThe Area of Functional Validation & Preclinical Research of CIBBIM-Nanomedicine obtains the ISO 9001:2008 certification of Quality Management System
This January, the Area of Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine has obtained the ISO 9001:2008 certification of Quality Management Systems for functional validation, preclinical development and/or...
Read moreAsdent donates more than 114,000 euros for the investigation of Dent’s disease in Vall d’Hebron
Asdent (Association of Dent Disease) has delivered 114,978.55 euros to the Vall d’Hebron Research Institute (VHIR) to continue researching this disease. The pathology of Dent is a hereditary minority disease linked to the X chromosome and...
Read moreProven the use of the polyurethane nanoparticle and poliurea (PUUa) for the improvement of therapy against cancer
The national consortium led by the research group of Addressing and Drug Release CIBBIM – Nanomedicine of the Vall d’Hebron Research Institute (VHIR) and led by Dr. Ibane Abasolo, has shown improvement in the effectiveness and...
Read moreProven that a protein produced by the kidney could become a therapeutic target for the metabolic syndrome
A study led by Dr. Anna Meseguer, chief of the group of research CIBBIM-Nanomedicine Renal Pathophysiology of the Vall d’Hebron Research Institute (VHIR), has showed the role of the KAP protein in the control of the development of the metabolic...
Read moreLearned lessons from a primary immunodeficiency: a study by Dr. Joan Sayos
Last September, the journal of Immunology published a new article in the series «The Pillars of Immunology», which reminds the classics that have promoted the knowledge of modern immunology. In this case, the study published has been based in the...
Read more6,8€ Million Granted to nTRACK Horizon 2020 Project, in which VHIR participates, to study multimodal nanoparticles as contrasts imaging agents for muscle regeneration
The European Union has awarded a grant of 6,8 million Euro to nTRACK collaborative project, which will officially be launched on the 16th of October in Barcelona. The goal of the nTRACK project is to develop a highly sensitive multimodal...
Read moreCaixaImpulse selects a VHIR project to combat multiresistant infections
El projecte ThermoShot™-FlashShot™: Nova tecnologia per combatre les infeccions multiresistents o les produïdes per dispositius mèdics que produeixen biopel·lícules forma part dels 23 treballs seleccionats en la tercera convocatòria del Programa...
Read moreNANOMEDICINE AND FUTURE, explained by Simó Schwartz, Director of U20 of NANBIOSIS
NANBIOSIS-U20 Scientific Director, Simó Schwartz, speaks about Nanomedicine in an interview publish in http://www.quimicaysociedad.org. NANBIOSIS is an Singular Scientific Technological Infrastructure (ICTS) that provides a complete service for...
Read moreThe EU-NCL network will support a project of nanomedicine for prostate cancer
The European Nanomedicine Characterisation Laboratory (EU-NCL) has selected a project from VHIR intended to develop a therapeutic nanoconjugate that improves the treatment of prostate cancer. The project is coordinated by Dr. Simó Schwartz Jr...
Read moreNanoparticles against cancer in the Live Research Fair
Can we improve the treatment of cancer with the help of nanoparticles? How can we help improve the effectiveness of a drug? Which treatment works best? And how can we test it? These are some of the questions that the group if Functional...
Read more